Last updated: April 26, 2026
What is the product and how is it used in clinical care?
“Theophylline 0.16% and Dextrose 5% in plastic container” is a parenteral, dextrose-containing formulation intended to deliver theophylline intravenously. In practice, the drug category is used to treat reversible airflow obstruction in obstructive airway disease, with theophylline acting as a bronchodilator and as a phosphodiesterase inhibitor.
Key formulation facts (by product description)
- Theophylline concentration: 0.16% (w/v)
- Dextrose concentration: 5% (w/v)
- Container: Plastic container
- Route: Intravenous (implied by parenteral “in plastic container” presentation in standard labeling conventions)
What is the current clinical development and trial landscape for this specific combination?
No complete, reliable, drug-specific clinical trial dataset tied to the exact combination label “theophylline 0.16% and dextrose 5% in plastic container” is available from public trial registries in a way that supports an accurate update without risking misattribution to other theophylline strengths, other diluents, oral products, or different branded presentations.
Given that constraint, the clinically actionable view for this combination is dominated by established use rather than active late-stage development.
Practical clinical positioning (what matters for trial activity)
- Theophylline is a mature molecule with longstanding clinical use.
- Combination with dextrose 5% is typically a formulation and compatibility choice rather than a distinct mechanism-changing product.
- Trial activity tends to be driven by new chemical entities, new delivery systems, or new dosing strategies; this pairing is more commonly part of the approved formulation portfolio than a frequent subject of new registrational trials.
What does the market look like for IV theophylline products in dextrose?
The market for IV theophylline is structurally shaped by:
- Maturity of the molecule
- Narrow therapeutic index management requirements (monitoring and risk profile)
- Shift toward alternative bronchodilators and airway therapies in many treatment pathways
- Hospital supply chain dependence on a limited set of injectable presentations
Demand drivers
- Hospital use for acute exacerbations where IV administration is chosen over oral routes.
- Formulary preferences tied to stability, compatibility, nursing handling, and availability (plastic container supply chain).
- Availability of theophylline injection SKUs in the required concentrations and diluents.
Constraint drivers
- Monitoring burden: theophylline levels require therapeutic drug monitoring in many settings.
- Therapeutic competition: other bronchodilators (short-acting beta agonists, anticholinergics) and newer supportive regimens often reduce the share of theophylline use.
- Tight supplier set: injectable niche SKUs can be exposed to manufacturing disruptions and regulatory scrutiny.
Segment definition used for projection
For business forecasting, the relevant commercial unit is not “theophylline overall,” but IV theophylline injection SKUs with:
- IV route
- dextrose-containing diluent presentation
- plastic container presentation
How do regulatory and labeling considerations affect supply and uptake?
For legacy injectables, the controlling variables are usually:
- Approved labeling and distribution continuity
- Manufacturing site compliance
- Product discontinuation risk for lower-volume SKUs
- Substitution pressure toward alternative strengths, alternative carriers, or different bronchodilator strategies
From a portfolio perspective, the key business risk is not clinical failure. It is availability and substitutability.
What is the competitive landscape for this exact presentation?
Competition comes from three directions:
- Other IV theophylline strengths or carriers (different diluents or concentration formats)
- Alternative IV bronchodilator pathways used in acute airway management
- Oral theophylline where conversion is clinically feasible (less relevant in acute IV-only situations)
Because this specific pairing is a formulation SKU, the closest substitutes are other theophylline IV presentations with compatible dosing equivalence and similar administration workflows.
Market projection: where the next 3 to 5 years are likely to land
A defensible projection without mislabeling requires a verified baseline (current volumes, price, and market share by SKU). That baseline is not available in the public domain in a way that supports a complete and accurate forecast for this exact “0.16% theophylline + 5% dextrose, plastic container” combination.
Accordingly, the only projection structure that can be stated as fact is scenario logic based on known market mechanics for mature injectables:
- Base-case: stable demand with sensitivity to hospital formularies and supplier continuity.
- Downside: SKU discontinuation or substitution by other airway management standards reduces attainable volume growth.
- Upside: supply continuity and formulary inclusion maintain steady pricing power within hospital budgets.
Which KPIs should investors and R&D leaders track for this SKU?
These are the KPIs that correlate with purchasable volume for injectable legacy products:
- National hospital account penetration (formulary listing and conversion behavior)
- SKU-level availability (days-of-supply, stockout frequency)
- Price per vial / per mg equivalence trend against substitute presentations
- Therapeutic drug monitoring practice adoption (influences clinician willingness to use theophylline)
- Adverse event and recall history tied to manufacturing lots (drives short-term demand shifts)
What is the near-term action plan for commercialization and portfolio decisions?
Given the mature nature of the molecule and the formulation SKU role of the product:
- Commercial focus: lock in contracts with hospital distribution channels where IV theophylline is used in acute workflows.
- Supply focus: prioritize manufacturing reliability and packaging stability for plastic container performance.
- Medical focus: align with standard monitoring workflows and dosing protocols to reduce resistance from clinicians.
Key Takeaways
- Theophylline 0.16% with dextrose 5% in plastic container is an IV formulation SKU where demand is driven by hospital acute airway protocols and supply continuity rather than new clinical breakthroughs.
- Public clinical trial data does not support a complete, accurate, drug-SKU-specific development update for this exact combination.
- Market outlook is structurally stable but exposed to SKU-level discontinuation and substitution by alternative acute airway management pathways.
- The most predictive business signals are SKU availability, hospital formulary inclusion, and price movement versus injectable substitutes.
FAQs
1) Is there active late-stage development for this exact theophylline + dextrose IV formulation?
No complete, verifiable public-trial dataset supports an accurate, SKU-specific late-stage development update for this exact combination presentation.
2) What substitutes compete most directly with this SKU in hospitals?
Other IV theophylline injection presentations (different concentrations and/or carriers) and non-theophylline IV acute airway management pathways that reduce reliance on IV theophylline.
3) What makes IV theophylline commercially harder than many other hospital injectables?
Therapeutic drug monitoring requirements and a narrow therapeutic index that can limit clinician adoption and increase protocolization needs.
4) How should forecast models be built given limited public SKU-level visibility?
Anchor projections on SKU availability, formulary penetration, and price per mg equivalence versus close injectable substitutes, not on molecule-level market trends alone.
5) What single factor most affects near-term revenue for this product?
Whether the specific plastic-container SKU remains reliably available to the hospital distribution network and stays listed in relevant formularies.
References (APA)
[1] ClinicalTrials.gov. (n.d.). Clinical trials database. U.S. National Library of Medicine. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
